OR WAIT null SECS
Protagen, BioAnalytix and GeneWerk merger set to target biopharma, C> sectors
After originally announcing the merger in July 2021, Protagen Protein Services GmbH, BioAnalytix, Inc. and GeneWerk GmbH are unifying their operations, and will be re-branding to form ProtaGene, a contract research organization (CRO) for both the biopharma and cell & gene therapy (C>) industries.
Protagen Protein Services, a global analytic CRO with knowledge in protein science, and BioAnalytix, an advanced analytics and data analysis firm, merged back in April 2019. GeneWerk, who offers services in vector safety, integration site analysis, and bioinformatics, merged into the group in 2021, creating ProtaGene.
According to the involved parties, all three of the companies’ combined experience provides an advanced, integrated, and complete protein and gene analytic service offering for biological therapeutics and C> platforms, starting from discovery, all the way to commercialization.
“Our collective expertise and unwavering delivery in both protein and gene analytics are well established,” says Kirtland Poss, CEO-US of ProtaGene and the founder of BioAnalytix. “By combining our capabilities, platforms and knowledge, we can now provide our U.S.-based biopharmaceutical and gene therapy customers advanced access to the broadest analytical offering from discovery to market, from a single vendor relationship.”